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Background: Most HIV strains that enter the brain are macrophage-tropic and use the CCR5 receptor to bind and infect
target cells. Because the cytoskeleton is a network of protein filaments involved in cellular movement and migration, we
investigated whether CCR5 and the cytoskeleton are involved in endothelial-mononuclear phagocytes interactions,
adhesion, and HIV-1 infection.
Results: Using a cytoskeleton phospho-antibody microarray, we showed that after co-culture with human brain
microvascular endothelial cells (HBMEC), HIV-1 infected monocytes increased expression and activation of cytoskeleton-
associated proteins, including Rac1/cdc42 and cortactin, compared to non-infected monocytes co-cultured with
HBMEC. Analysis of brain tissues from HIV-1-infected patients validated these findings, and showed transcriptional
upregulation of Rac1 and cortactin, as well as increased activation of Rac1 in brain tissues of HIV-1-infected humans,
compared to seronegative individuals and subjects with HIV-1-encephalitis. Confocal imaging showed that brain cells
expressing phosphorylated Rac1 were mostly macrophages and blood vessels. CCR5 antagonists TAK-799 and maraviroc
prevented HIV-induced upregulation and phosphorylation of cytoskeleton-associated proteins, prevented HIV-1 infection
of macrophages, and diminished viral-induced adhesion of monocytes to HBMEC. Ingenuity pathway analysis suggests
that during monocyte-endothelial interactions, HIV-1 alters protein expression and phosphorylation associated with
integrin signaling, cellular morphology and cell movement, cellular assembly and organization, and post-translational
modifications in monocytes. CCR5 antagonists prevented these HIV-1-induced alterations.
Conclusions: HIV-1 activates cytoskeletal proteins during monocyte-endothelial interactions and increase transcription
and activation of Rac1 in brain tissues. In addition to preventing macrophage infection, CCR5 antagonists could diminish
viral-induced alteration and phosphorylation of cytoskeletal proteins, monocyte adhesion to the brain endothelium and
viral entry into the central nervous system.
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Despite the successes of antiretroviral therapy, the brain re-
mains a major target for HIV infection and a major viral
reservoir. This viral infection of the CNS commonly results
in behavioral, motor, and cognitive impairments termed
HIV-1-associated neurocognitive disorders (HAND) [1,2].
Disease pathology is characterized by the presence of
microglial nodules and multinucleated giant cells, and in-
cludes brain atrophy, gliosis, and neuronal loss, all* Correspondence: gkanmogne@unmc.edu
1Department of Pharmacology and Experimental Neuroscience, University of
Nebraska Medical Center, Omaha, Nebraska 68198-5800, USA
Full list of author information is available at the end of the article
© 2014 Woollard et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcollectively termed HIV encephalitis (HIVE) [3]. HIV-
infection of the CNS is fueled by viral infection and im-
mune activation of mononuclear phagocytes (MPs), which
promote monocyte trafficking across the blood–brain bar-
rier (BBB) and spread of infection to resident brain cells [4].
HIV enters target cells by binding the envelope glyco-
protein gp160 to the CD4 receptor and/or co-receptors
such as CCR5 and CXCR4 [5-8]. The new class of anti-
retroviral drugs called entry inhibitors act by binding the
CD4 receptor, CCR5 or CXCR4 co-receptors, to prevent
viral binding and entry into cells. One of those entry in-
hibitors, maraviroc, is a small molecule CCR5 antagonist
that is currently FDA-approved for the treatment ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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[9-12]. TAK-779 is another small molecule non-peptide
CCR5 antagonist that has been shown to suppress HIV-1
envelope-mediated membrane fusion [13] and reduce in-
flammation [14]. We previously demonstrated that human
brain microvascular endothelial cells (HBMEC) lack the
CD4 receptor but expressed both CCR5 and CXCR4 co-
receptors [15].
Most HIV strains that cross the BBB, enter the brain,
and infect CNS cells are M-tropic and use CCR5 to enter
and infect target cells [16,17]. Therefore, we hypothesized
that CCR5 plays a major role in monocyte-brain endothe-
lium interactions and HIV entry into the CNS and that
CCR5 blockers would abrogate these effects. Because
the cytoskeleton is responsible for cellular morphology
and motility, we further hypothesized that HIV-induced
monocyte-endothelial interactions and trans-endothelial
migration involve cytoskeletal changes and that CCR5
blockers would also affect these changes. In the current
study, we used a cytoskeleton phospho-antibody array to
investigate changes in the expression and activation of
cytoskeleton-associated proteins in monocytes following
HIV-1 infection and endothelial interaction. We further
used CCR5 antagonists (TAK-779 and maraviroc) and anti-
bodies to determine the role of CCR5 on HIV-1 infection
of monocytes-derived macrophages (MDM), monocyte-
endothelial interaction, and cytoskeletal changes. Data sug-
gest that interaction of HIV-infected monocytes with
HBMEC is associated with altered expression and activa-
tion of monocytes cytoskeletal proteins. CCR5 blockers
can reverse those changes and prevent MDM infection.
Most importantly in support of these findings, we showed
increased transcription of cortactin gene (CTTN) and
RAC1, and increased phosphorylation of Rac1 at serine-71
(S71) in brain tissues of HIV-1-infected patients. Confocal
imaging showed that phospho-Rac1 was mostly expressed
in brain macrophages and blood vessels. Cortactin and
Rac1 are cytoskeletal proteins that have been shown to be
involved in cytoskeletal remodeling, cellular motility, cell-
cell adhesion, and leukocyte transmigration [18-20]. This
suggests that HIV-1-induced endothelial-monocyte inter-
actions and transmigration of infected MPs into the brain
is associated with increased transcription, expression and
activation of MPs cytoskeletal proteins, and CCR5 blockers
could diminish these alterations.
Results
CCR5 blockers prevent HIV-1 infection of macrophages
CCR5 blockers such as maraviroc have been shown to block
entry of M-tropic HIV into target cells [9], and maraviroc is
currently FDA-approved for the treatment of individuals in-
fected with M-or dual-tropic HIV [9-12]. To confirm the ef-
fects of CCR5 blockers in vitro, we infected human MDM
with HIV-1 in the presence of TAK-779 or maraviroc andassessed viral replication by reverse transcriptase assay. Both
maraviroc (Figure 1A-F) and TAK-779 (Figure 1G-L) signifi-
cantly diminished MDM infection. From day-5 to day-18
post-infection (p.i), maraviroc diminished MDM infec-
tion by 7.2- to 44-fold (Figure 1A-F), while TAK-779 di-
minished MDM infection by 4.8- to 15.3-fold (Figure 1G-L).
Additional experiments showed that TAK-779 and mara-
viroc concentrations as low as 0.05 μM significantly de-
creased viral infection (data not shown).
Effects of CCR5 blockers on cellular viability and brain
endothelial barrier functions
To ensure that the observed anti-viral effects of CCR5
blockers were not due to inadvertent drug toxicity on
macrophages, we tested the effects of TAK-779 and mara-
viroc on MDM viability. Results from day-5 to day-12 p.i.
showed that TAK-779 or maraviroc did not alter MDM
viability (data not shown). To determine whether CCR5
blockers could alter endothelial barrier properties and
function, we assessed their effects on the brain trans-
endothelial electrical resistance (TEER). Exposure of
HBMEC to 5, 10, or 20 μM TAK-779 (Figure 2A) or mara-
viroc (Figure 2B) did not alter TEER. HIV-1 infection in-
creased monocyte adhesion to HBMEC, and both CCR5
antagonists and neutralizing CCR5 antibodies significantly
decreased HIV-induced monocyte adhesion (Figure 2C).
Increased expression of cytoskeletal proteins in HIV-infected
monocytes following monocyte-endothelial interactions
During leukocytes interactions with other immune cells, cel-
lular cytoskeletons undergo major changes and reorganization
that facilitates leukocyte motility and migration [21-23].
We determined the cytoskeleton-associated protein changes
in monocytes during monocyte-endothelial communication
in the presence or absence of the CCR5 blocker TAK-779.
Protein microarray showed that compared to non-
infected monocytes, two-hour co-culture of HIV-
infected monocytes with HBMEC induced upregulation
of cytoskeleton-associated proteins in monocytes, with
13 proteins upregulated by 2-fold or more (Table 1),
while expression of the remaining 128 cytoskeleton-
associated proteins was not significantly changed or did
not meet the 2-fold cut-off. TAK-779 prevented HIV-
induced upregulation of cytoskeleton-associated pro-
teins during monocyte-endothelial interactions (Table 1,
Additional file 1: Figure S1).
Altered phosphorylation of cytoskeleton-associated proteins
in HIV-infected monocytes during monocyte-endothelial
interactions
Post-translational modifications such as phosphorylation
play a major role in the regulation of protein function,
protein-protein interactions, and cellular function [22].
Because minor changes in phosphorylation level can have
Figure 1 (See legend on next page.)
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Figure 1 CCR5 antagonists inhibits HIV-1 infection in MDM. MDM were infected with the macrophage tropic HIV-1ADA, with or without maraviroc
or TAK-779 (5 μM) in the media. Controls consisted of mock-infected cells. Culture supernatants were then collected every 2 or 3 days from day-5 to
day-18 post-infection (p.i) and viral replication estimated by quantifying reverse transcriptase activities. From day-5 to day-18 p.i., both maraviroc (A-F)
and TAK-779 (G-L) inhibited HIV-1 infection of MDM (***P < 0.001). This is representative data from 3 independent experiments with 3 different human
donors, with each donor tested in triplicate.
Figure 2 Effects of CCR5 antagonists on the BBB integrity and
function. Confluent HBMEC monolayers were treated with TAK-799
(A) or maraviroc (MVR) (B), and TEER measured in real-time before and
after exposures. At 5, 10, or 20 μM, TAK-799 (A) or maraviroc (B) did
not alter TEER. TEER values were similar during treatment and when
cells were washed to remove CCR5 antagonists. Controls consisted of
mock-treated cells and cells treated with 0.1% saponin. Saponin-
induced decrease in TEER was reversed upon removal of saponin from
the media. (C) HIV-1 increased monocyte adhesion to HBMEC and
CCR5 antagonists and neutralizing CCR5 antibodies decreased viral-
induced monocyte adhesion (**P < 0.01; ***P < 0.001).
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to analyze proteins differentially phosphorylated in HIV-
1-infected monocytes following monocyte-endothelial co-
culture, compared to infected monocytes treated with the
CCR5 blocker and non-infected monocytes co-cultured
with HBMEC. Normalization of each phospho-protein to
the expression of its corresponding total protein showed
that phosphorylation of 9 proteins increased by 1.5-fold or
more, while phosphorylation of 12 proteins decreased by
1.5-fold or more, and 33 proteins had no significant
change in phosphorylation level. Normalization of protein
expression to the sample’s actin levels revealed increased
phosphorylation in 33 proteins, decreased phosphoryl-
ation in 7 proteins, while 25 proteins had no significant
change in phosphorylation levels. Phospho-proteins that
showed significant differential expression using both
normalization methods included 3 proteins with de-
creased phosphorylation and 8 cytoskeleton-associated
proteins with significantly increased phosphorylation
(Table 2). HIV-1 infection and endothelial-monocyte in-
teractions increased the phosphorylation of Merlin
(Ser518), vasodilator-stimulated phosphoprotein (VASP)
(Ser157), Rac1(S71), cortactin (Tyr421), and ERK1/2
(Tyr204/202) by 4.5 to 6.3-fold, 4-fold, 2.3- to 3.6-fold,
2 to 3-fold, and 2.4 to 2.6-fold respectively (Table 2).
TAK-779 prevented HIV-induced phosphorylation of
these cytoskeleton-associated proteins during monocyte-
endothelial interactions (Table 2, Additional file 1: Figure S1).
Ingenuity pathway analysis (IPA) of differentially expressed
and phosphorylated proteins showed that the major bio-
logical functions associated with these cytoskeleton-
associated proteins and phosphorylation network included
cellular assembly and organization, cellular movement,
cell morphology, post-translational modification, cell cycle
and cell-to-cell signaling (Additional file 2: Table S1).
Canonical pathways activated in HIV-infected monocytes
co-cultured with HBMEC included chemokine and integ-
rin signaling, and cell junction signaling (Additional file 3:
Table S2).
Confirmation of non-productive HIV-1 infection of
monocytes
It is known that HIV-1 does not productively infect hu-
man monocytes, and even for monocytes-derived macro-
phages, productive infection (detectable p24 or reverse
transcriptase activity) is often seen from day-3 post-
infection. To determine whether non-productive infection
Table 1 Differently expressed total proteins in HIV-infected-monocytes co-cultured with HBMEC
Protein HIV vs. control fold change P-value HIV vs. TAK fold change P-value Location
Src 3.05 5.09E-10 0.67 3.34E-05 Cytoplasm
MKK3/MAP2K3 2.78 3.62E-09 0.41 1.16E-11 Cytoplasm
PKC alpha 2.56 7.34E-08 0.57 6.81E-06 Cytoplasm
p130Cas 2.51 2.06E-08 0.54 1.16E-11 Plasma membrane
MKK7/MAP2K7 2.41 5.47E-09 0.45 1.16E-11 Cytoplasm
CaMK2-beta/gamma/delta 2.40 1.61E-09 0.69 3.61E-04 Nucleus
Ezrin 2.22 4.15E-10 0.50 1.16E-11 Plasma membrane
PLC beta3 2.17 3.62E-09 0.48 1.09E-06 Cytoplasm
c-Raf 2.07 1.99E-11 0.57 1.29E-11 Cytoplasm
PLC-beta 2.04 7.50E-07 0.53 2.09E-10 Cytoplasm
WAVE1 2.02 3.19E-06 1.17 1.61E-03 Nucleus
LIMK1 1.99 1.99E-11 0.46 3.08E-11 Cytoplasm
Myosin regulatory light chain 2 1.99 5.47E-09 0.63 7.03E-11 Cytoplasm
HBMEC: human brain microvascular endothelial cells; HIV: human immunodeficiency virus-1.
Unadjusted P values, P values adjusted for multiple comparisons using Tukey post-hoc test, and P values adjusted for false discovery rate using the Benjamini &
Hochberg method were all significant. Table show P values adjusted using the Benjamini & Hochberg method.
Src: v-src sarcoma viral oncogene homolog; MKK3/MAP2K3: mitogen-activated protein kinase kinase3; PKC: protein kinase C; p130Cas: breast cancer anti-estrogen
resistance 1; MKK7/MAP2K7: mitogen-activated protein kinase kinase 7; CAMK2: calcium/calmodulin-dependent protein kinase-2; PLC: phospholipase C; c-raf: v-raf-1
murine leukemia viral oncogene homolog 1; WAVE1: WAS protein family 1; LIMK1: LIM domain kinase 1.
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gp120 expression in freshly elutriated and HIV-exposed
monocytes cultured 2 to 48 hours in media with and with-
out human recombinant macrophage colony stimulating
factor (MCSF, induce monocyte differentiation to macro-
phage). Quantitative real-time PCR for HIV-1 gag mRNA
(Additional file 4: Figure S2A, B) showed that HIV-1 gag
mRNA was present in monocytes from 2 hours post elutri-
ation/infection, with more gag copies numbers in mono-
cytes cultured in media without MCSF (Additional file 4:
Figure S2B), compared to monocytes cultured in media con-
taining MCSF (Additional file 4: Figure S2A). Gag mRNA
copy numbers decreased over time but was still detectable
in infected cells. Reverse-transcription PCR targeting tat
mRNA (Additional file 4: Figure S2C, D) also showed de-
tectable tat mRNA in both monocytes cultured in media
with (Additional file 4: Figure S2C) and without (Additional
file 4: Figure S2D) MCSF from 2 hours post elutriation/in-
fection. Immunofluorescence analysis using gp120 monoclo-
nal antibodies also showed positive staining for HIV-1
gp120 in monocytes from 2 hours post elutriation/infection
(Additional file 5: Figure S3).
Increased transcription of cortactin and Rac1, and Rac1
activation in brain tissues of HIV-infected patients
To determine whether our in vitro findings correlated with
changes in HIV-infected humans, we analyzed brain tissues
of 12 HIV-1,2-seronegative control subjects, 9 HIV-1-
seropositive patients without evidence of HIVE, and 10
HIV-1-seropositive patients with HIVE and HAND. All
brain tissues were from the cortex region, with 28 of the31 samples from the frontal cortex, 2 samples from the
parietal cortex, and 1 sample from the temporal cortex.
Table 3 shows the age, gender, clinical history, post-
mortem interval (PMI) between the time of death and aut-
opsy, and a summary of post-mortem findings for all 31
human subjects. For seronegative controls, HIV-infected,
and HIVE patients, the age ranges in years were respect-
ively 32 to 72 (mean: 52±13.4), 27 to 54 (mean: 41.78±8.8),
and 30 to 52 (mean: 40.6±7.76). For seronegative controls,
HIV-infected, and HIVE patients, the PMI ranges in hours
were respectively 3 to 8.5 (mean: 4.6±1.6), 2.75 to 15
(mean: 8.5±4), and 4 to 21 (mean: 9.45±5.16). No signifi-
cant differences were detected in age and PMI between the
seronegative, HIV-1-infected, or HIVE groups.
Quantitative real-time PCR (qRT-PCR) showed tran-
scriptional upregulation of RAC1 and CTTN in brain tis-
sues from HIV-1-infected patients. Compared to brain
tissues from seronegative and HIVE patients, brain tissues
from HIV+ patients had 3-fold and 4-fold higher RAC1
mRNA respectively (Figure 3A, B, P < 0.01), and had 2.4-
fold (P < 0.001) and 1.6-fold (P < 0.01) higher CTTN
mRNA respectively (Figure 3C, D).
Analysis of Rac1 activation in human brain tissues
showed significantly increased levels of phosphorylated
Rac1(S71) in brain tissues from HIV+ patients, compared
to brain tissues from seronegative controls and HIVE pa-
tients (Figure 4A-D). Additional western blot experiments
confirmed our protein microarray results and showed that
HIV-1 infection increased phosphorylation of Rac1 at S71,
and phosphorylation of ERK1/2 in human monocytes fol-
lowing monocyte-endothelial communication, and the
Table 2 Phosphorylated proteins differentially expressed when normalized to total proteins or actin levels
Phospho-protein/total protein HIV vs. CONTROL HIV + TAK vs. CONTROL HIV vs. HIV + TAK
Name Fold change P-value Fold change P-value Fold change P-value
Merlin (Phospho-Ser518) 4.47 8.13E-12 1.39 8.97E-05 0.31 1.45E-10
VASP (Phospho-Ser157) 4.05 8.13E-12 1.29 0.00047 0.32 1.84E-11
ERK1-p44/42 MAP Kinase (Phospho-Tyr204) 2.38 4.31E-08 1.14 0.10 0.48 3.68E-09
Rac1/cdc42 (Phospho-Ser71) 2.24 1.28E-05 0.85 0.17 0.38 1.76E-07
Cortactin (Phospho-Tyr421) 1.20 8.13E-12 0.63 1.53E-10 0.31 1.84E-11
CaMK1-a (Phospho-Thr177) 1.93 5.75E-05 1.47 0.0092 0.76 0.00013
ERK1-p44/42 MAP Kinase (Phospho-Thr202) 1.74 6.72E-08 1.15 1.13E-05 0.66 3.71E-06
ERK3 (Phospho-Ser189) 1.68 7.74E-05 1.10 0.556 0.65 0.0035
MEK1(Phospho-Ser217) 1.47 0.00017 0.83 0.00034 0.57 4.63E-06
MKK6 (Phospho-Ser207) 0.49 8.13E-12 0.49 1.53E-10 1.01 0.96
FAK (Phospho-Tyr397) 0.44 8.13E-12 0.87 0.0552 1.97 8.0E-09
MKK7/MAP2K7 (Phospho-Ser271) 0.30 8.13E-12 0.81 0.0344 2.65 1.54E-09
Phospho-protein/actin HIV vs. CONTROL HIV + TAK vs. CONTROL HIV vs. HIV + TAK
Name Fold change P-value Fold change P-value Fold change P-value
Merlin (Phospho-Ser518) 6.24 1.95E-11 1.15 0.079 0.184 1.16E-11
VASP (Phospho-Ser157) 4.38 1.95E-11 0.88 0.088 0.20 1.16E-11
Rac1/cdc42 (Phospho-Ser71) 3.56 3.67E-08 0.83 0.14 0.23 6.98E-10
ERK1-p44/42 MAP Kinase (Phospho-Tyr204) 3.26 9.42E-10 0.88 0.13 0.27 1.16E-11
Cortactin (Phospho-Tyr421) 2.93 1.96E-11 0.73 7.19E-08 0.25 1.16E-11
ERK1-p44/42 MAP Kinase (Phospho-Thr202) 2.55 1.2E-10 0.92 0.0028 0.34 3.18E-11
MEK1(Phospho-Ser217) 2.23 2.06E-08 0.74 2.35E-06 0.33 7.81E-10
CaMK1-a (Phospho-Thr177) 1.67 0.00038 1.08 0.91 0.64 3.19E-07
ERK3 (Phospho-Ser189) 1.61 0.00011 1.06 0.91 0.65 0.0026
MKK7/MAP2K7 (Phospho-Ser271) 0.73 1.51E-06 0.87 0.23 1.18 0.038
FAK (Phospho-Tyr397) 0.61 1.96E-11 0.64 2.82E-06 1.05 0.63
MKK6 (Phospho-Ser207) 0.60 1.96E-11 0.71 2.27E-06 1.17 0.00089
P-values were adjusted using the Benjamini & Hochberg test.
Unadjusted P values, P values adjusted for multiple comparisons using Tukey post-hoc test, and P values adjusted for false discovery rate using the Benjamini &
Hochberg method were all significant. Table show P values adjusted using the Benjamini & Hochberg method.
VASP: vasodilator-stimulated phosphoprotein; CaMK1: calcium/calmodulin-dependent protein kinase-1; ERK: extracellular signal-regulated kinases; MEK / MKK:
mitogen-activated protein kinase kinase; FAK: focal adhesion kinase.
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HIV-induced phosphorylation of Rac1 and ERK1/2
(Figure 4E).
To determine which cell type in the human brain ex-
presses phospho-Rac1 (S71), we analyzed brain tissue sec-
tions from seronegative controls, HIV+ and HIVE patients
by confocal microscopy. Data showed high expression of
pRac1 (S71) in brain macrophages (Figure 5A-C, white ar-
rows), and blood vessels, with pRac1(S71) mostly
expressed on vessels tight junction strands (Figure 5A, C,
G, J-M, orange arrows). Many samples did not show
pRac1 expression in microglia (Figure 5D, E), but some
HIVE patients showed pRac1 expression in microglia
(Figure 5F, white arrows). No sample showed pRac1
(S71) expression in astrocytes (Figure 5G-I) or neurons
(Figure 5J, K). Because lipofuscin-like pigments canaccumulate in human brain and autofluoresce over a
broad excitation and emission spectra [24], we used a
4th laser line (excitation: 543-nm, emission: 595-nm) to
differentiate autofluorescent pigments from antibody
staining. These autofluorescent pigments are shown in
white (Figure 5, yellow arrows).
Discussion
Chemokine receptors such as CCR5 and CXCR4 play a
major role in HIV-entry into target cells and viral infection
[5-8]. Maraviroc, a slowly reversible CCR5 antagonist [9]
and the only FDA-approved entry inhibitor, is currently
used for the treatment of patients infected with M-tropic
and dual-tropic HIV strains [9,25,26]. HIV infection and
immune activation of MPs promotes monocyte-endothelial
interactions and increased entry of MPs into the CNS
Table 3 Clinical history of brain tissues donors
HIV-1 status ID Gender/Age (y) PMI (h) Neurocognition/Neuropathology Other autopsy diagnosis
Neg N1 M/35 8.5 Normal/None Mild Alzheimer gliosis
Neg N2 N/A N/A Normal/None N/A
Neg N3 F/38 5.75 Normal/Not significant Mild gliosis, lung and bile
duct carcinoma
Neg N4 M/32 4.25 Normal/Not significant Cystic fibrosis, and multiorgan
failure
Neg N5 F/46 4 Normal/Not significant Mild fibrosis, mild patchy gliosis
Neg N6 F/49 4.5 Normal/Not significant Hepatic cirrhosis, liver failure
Neg N7 M/52 5.25 Normal/None Hypertension, renal failure
Neg N8 M/72 3 Normal/None Hypertension, COPD
Neg N9 M/64 3.3 Normal/None Hepatic carcinoma
Neg N10 M/56 3 Normal/Not significant Lung adenocarcinoma, mild
nonspecific cortical atrophy
Neg N11 M/67 3.5 Normal/None COPD, TB
Neg N12 M/61 5.75 Normal/Not significant Cardiomyopathy, mild gliosis
Pos P1 ?/46 2.75 Normal/None N/A
Pos P2 ?/27 8 Normal/None N/A
Pos P3 ?/37 5 Normal/None N/A
Pos P4 M/39 11 Normal/None Minimal non-diagnostic
abnormalities
Pos P5 M/35 6.5 Normal/None Non-Hodgkins lymphoma, AIDS
Pos P6 M/54 6.5 Normal/None AIDS
Pos P7 M/48 15 Normal/None Liver disease
Pos P8 M/52 8 Normal/None AIDS
Pos P9 M/38 14 Normal Pneumonia, hemophilia A, AIDS
Pos HAD1/D1 M/30 6 HAD/HIVE Minimal terminal anoxia
Pos HAD2/D2 ?/50 21 HAD/HIVE N/A
Pos HAD3/D3 ?/39 12 HAD/HIVE N/A
Pos HAD4/D4 ?/40 12 HAD/HIVE N/A
Pos HAD5/D5 M/47 11 HAD/HIVE Encephalopathy, microglial nodule
encephalitis, meningoencephalitis
with microvascular damage
Pos HAD6/D6 M/40 5 HAD/HIVE Non-Hodgkin’s lymphoma, AIDS,
lymphocytic meningitis
Pos HAD7/D7 M/44 4 HAD/HIVE Microglial nodules, astrocytosis,
widespread gliosis, AIDS
Pos HAD8/D8 M/52 5 HAD/HIVE Atherosclerosis
Pos HAD9/D9 M/34 11.5 HAD/HIVE AIDS
Pos HAD10/D10 M/38 7 HAD/HIVE HIV encephalopathy/
Leukoencephalopathy, AIDS
Neg indicates HIV seronegative; Pos, HIV seropositive; HAD, HIV-associated dementia; HIVE, HIV encephalitis; y, years; M, male; F, female; ? or N/A, not available;
and PMI, postmortem interval; AIDS, acquired immunodeficiency syndrome; COPD: chronic obstructive pulmonary disease; TB, tuberculosis.
Woollard et al. Retrovirology 2014, 11:20 Page 7 of 16
http://www.retrovirology.com/content/11/1/20[4,27-29]. In the present study, we demonstrate that HIV-1
increases expression and activation of MPs cytoskeletal-
associated proteins during monocyte-endothelial interactions,
and CCR5 blockers diminished these effects, diminished
HIV-induced increase in monocyte adhesion to in vitro BBB
models, and prevented viral infection.Cytoskeletal-associated proteins activated following
monocyte-endothelial communications included Rac1. To
our knowledge, this is the first study to show that HIV-1
induced phosphorylation of Rac1 at S71 in MPs during
monocyte-endothelial interactions, and that this is likely
mediated by CCR5, since CCR5 antagonists diminished
Figure 3 Increased transcription of RAC1 and CTTN in brain tissues of HIV-infected humans. Quantitative real-time PCR show overall increase in
Rac1 (A, B) and cortactin (C, D) mRNA in brain tissues of HIV-positive individuals (HIV Pos, donors P1 to P9), compared to seronegative controls
(HIV Neg, donors N1 to N12) and HIV-infected patients with encephalitis (HIVE, donors D1 to D10).
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knowledge, to show that 1) HIV-1 infection in humans is as-
sociated with increased transcription of RAC1 and CTTN,
2) Rac1 phosphorylation at S71 is increased in HIV+ brain
tissues, and 3) cells expressing phosphorylated Rac1 (S71) in
the human brain were mostly associated with brain macro-
phages and blood vessels. It is known that tissue damage
such neuronal cell death and gliosis are common in HIVE,
and this is confirmed by our immunostaining showing re-
duced staining for the neuronal marker MAP2 in HIVE.
However, we do not believe that these tissue damages could
have impacted our results on cells expressing activated
Rac1, because analysis of brain tissues from HIV seronega-
tive controls, HIV+ cases without encephalitis, and HIVE
patients showed that activated Rac1 (S71) were mostly
expressed in brain macrophages and blood vessels, andnone of the sample analyzed showed expression of phos-
phorylated Rac1 (S71) in neurons or astrocytes.
Significant increases in transcription of RAC1 and CTTN
were observed only in brain tissues of HIV-infected indi-
viduals, compared to brain tissues of seronegative controls,
or infected patients with advanced neurological complica-
tions (HIVE), suggesting that HIV-induced transcriptional
regulation of RAC1 and CTTN occurs early in the course
of viral infection, which likely coincides with BBB breach
and increased trafficking of MPs into the CNS. HIV-
induced BBB dysfunction and the resulting increased entry
of MPs into the CNS are well-documented to precede sub-
sequent CNS complications such as HIVE and HAND
[27-29]. Previous studies also showed increased transcrip-
tional upregulation of proinflammatory cytokines such as
IL6, and STAT1, in brain tissues of HIV+/nonencephalitic
Figure 4 Increased phosphorylation of Rac1(S71) in brain tissues of
HIV-infected humans. (A-D) Western blot analyses show increased levels
of pRac1 (S71) in brain tissues of HIV-positive individuals (HIV Pos, donors
P8, P6, P5, P9, P2, and P4), compared to HIV-infected patients with
encephalitis (HIVE, donors D7, D6, D8, and D10) and seronegative controls
(HIV Neg, donors N5, N4, N7, N6, N11, and N12). (E) Increased levels of
pRac1 (S71) and pERK1 (Thr202/Tyr204) in HIV-infected monocytes
co-cultured with HBMEC, compared to non-infected monocytes co-
cultured with HBMEC. TAK-779 and maraviroc diminished HIV-induced
phosphorylation of Rac1 and ERK1/2.
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and HIVE patients [30], confirming that increased inflam-
mation and inflammation-induced damages that leads to
HIVE often precede the onset of HIVE. It has also been
demonstrated that Rac1 activation is associated with clus-
tering of cell adhesion molecules, increased production of re-
active oxygen species, and leukocyte transendothelial
migration [31,32]. In HIV-induced CNS dysfunction, such
oxidative stress events and leukocyte entry into the CNS
occur earlier following HIV infection, before the onset of
HIVE.
Ligand binding to chemokine receptors has been shown
to induce activation of signaling that regulate cellular integ-
rins and adhesion molecules, resulting in rearrangement of
the actin cytoskeleton, changes in cell morphology and mi-
gration [33]. This agrees with our current study, which
shows that proteins differentially expressed and activated in
HIV-infected monocytes following monocyte-endothelial
communications are associated with functions such as cel-
lular movement, cell morphology, cell-to-cell signaling, and
post-translational modifications. The signaling pathways
activated in HIV-infected monocytes following monocyte-
endothelial interaction included those associated with in-
tegrin and cell junction signaling.
Rac1 is a small signaling G protein that, when activated,
binds to other effector proteins to regulate cellular func-
tions such as cytoskeletal reorganization, cell-cell adhe-
sion, and motility [18], integrin- and cadherin-mediated
cell-cell adhesion [19]. Rac1 is the predominant Rac iso-
form in monocytes, accounting for 90% of Rac expression
[34]. It also has been shown that hepatitis-B virus activates
Rac1, which further induces ERK1/2, AKT, and STAT
phosphorylation [35]. Rac1 inactivation inhibits cell prolif-
eration and migration [36] while Rac1 S71 phosphoryl-
ation increases filopodial structures and enhances cell
motility and migration [37]. Previous studies in astro-
glioma cell lines also showed that Rac1 is activated during
HIV-induced cell fusion and this is mediated by co-
receptors and cytoskeletal actin [38], and Rac1 inhibitors
decreased adhesion of U937 cells to endothelial cells [39].
Our data showed overall higher levels of Rac1 mRNA and
pRac1(S71) in brain tissues from HIV-infected humans;
however, the levels were not uniform and some HIV pa-
tients had more Rac1 mRNA and pRac1(S71) than others.
Figure 5 Expression of pRac1 (S71) in human brain immune cells. Confocal microscopy shows expression of pRac1(S71) in human brain
macrophages (A-C, white arrows) and blood vessels tight junction strands (A, C, G, J-M orange arrows). Most brain tissues samples did not show
significant expression of pRac1 (S71) in microglia (D, E), but brain tissues of some HIVE patients showed pRac1(S71) in microglia (F, white arrows).
Data showed no expression of pRac1 (S71) in astrocytes (G-I) or neurons (J, K). For all experiments, a 4th laser line was used to differentiate
lipofuscin-like autofluorescent pigments from antibody staining (yellow arrows). Scale bar for all panels: 20 μM.
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study did not include viral loads, we do not know whether
this differential Rac1 activation and transcriptional regula-
tion is associated with increased plasma or CSF viremia.
Ample evidence indicates that G-protein couple recep-
tors such as CCR5 directly interact with the cytoskeleton
and Rac1, and these interactions affect infectivity and
migration. Binding of HIV-1 envelope glycoprotein to
the CD4 receptor and CCR5 or CXCR4 co-receptors in-
duces a signaling cascade that results in Rac1 activation
and actin cytoskeletal reorganizations, changes that are re-
quired for efficient viral-mediated membrane fusion and
infection [38,40]. Studies in macrophages and CCR5-
transfected cells also showed that CCR5 binding to its li-
gands induce signaling that results in Rac1 activation,
cytoskeletal reorganization and formation of lamellipodia,
and these effects are blocked by a Rac dominant negative
mutant [41].Our present study confirmed the antiviral activity of
maraviroc and also showed that both maraviroc and TAK-
779 at 0.5-5 μM (0.25-2.57 ng/ml) inhibit HIV-1 infection
of human macrophages without inducing additional cell
toxicities. Studies of humans on maraviroc treatment re-
ported a median (and range) maraviroc plasma concentra-
tions of 94.9 (21.4–478) ng/ml [42]; 124.75 (7.3-517) ng/
ml [43]; 123 (31.7–529) ng/ml [44]; and 347 (123–2678)
ng/ml [45]. Maraviroc could also be quantified in the CSF
of these patients, with median (and range) concentrations
of 3.6 (1.83-12.2) ng/ml; [42] 2.58 (0.5–7.22) ng/ml; [43]
and 102 (35–173) ng/ml [45]. The concentrations of
CCR5 antagonists used in our present study were much
lower than those reported in human plasma and CSF
[42-45], thus indicating that our findings are relevant to
in vivo situations in humans.
In addition to their antiviral effects, CCR5 blockers can
have other beneficial effects on the immune system.
Woollard et al. Retrovirology 2014, 11:20 Page 11 of 16
http://www.retrovirology.com/content/11/1/20Maraviroc concentrations of 0.1-4 μM lowers lipopoly-
saccharide-induced inflammation in adipocytes, de-
creasing mRNA and secretion of MCP-1, IL-8, and IL-6
[46]. Maraviroc treatment improves progressive multifocal
leukoencephalopathy-immune reconstitution inflammatory
syndrome [47] and improves lipid profiles in HIV patients
with dyslipidemia [48]. Maraviroc also has CNS antiviral
and metabolic activities that include significant reduction in
plasma and CSF viral load of patients with neurological im-
pairment [45], and increased NAA/creatinine levels [49],
suggesting that maraviroc improved neuronal integrity. Ex
vivo and in vitro studies showed that maraviroc significantly
reduced inflammation and the chemotactic activities of
peripheral blood mononuclear cells, T-lymphocytes,
dendritic cells, monocytes and macrophages [50-52],
and decreased lipopolysaccharide-induced MMP9 ex-
pression in astrocytes and microglia [53]. These findings
showed that maraviroc could reduce inflammation and
leukocyte trafficking into the CNS. Our current data
showed that CCR5 blockers and CCR5 antibodies reduce
HIV-induced monocyte adhesion to in vitro BBB models.
Adhesion precedes leukocyte migration and trafficking,
which suggests that CCR5 blockers and CCR5 antibodies
can reduce leukocyte trafficking across the BBB. Most im-
portantly, our data suggest that HIV infection in humans
is associated with transcriptional regulation and activation
of Rac1 in the CNS, and CCR5 blockers such as maraviroc
could prevent Rac1 activation and improve HIV-induced
CNS complications in infected humans.
Conclusions
HIV-1 increases expression and activation of MPs
cytoskeletal-associated proteins during monocyte-
endothelial interactions, and CCR5 blockers dimin-
ished these effects, diminished HIV-1-induced increase
in monocyte adhesion to in vitro BBB models, and pre-
vented viral infection. These findings are important
and have implications in cell-to-cell interactions and
signaling, in HIV-1 infection and viral entry into the
brain, and subsequent neurological complications.
Eliminating or reducing viral reservoir is important for
combatting HIV/AIDS and reducing disease burden,
and the current study suggest that antiretroviral regi-
mens containing CCR5 blockers such as maraviroc
could reduce cellular trafficking across the brain endo-
thelium, viral entry into the CNS and disease burden.
Methods
Monocyte isolation and HIV-1 infection
Human monocytes were obtained from HIV-1-, HIV-2-,
and hepatitis B-seronegative donor leukocytes and sepa-
rated by countercurrent centrifugal elutriation and in-
fected with HIV-1ADA, a clade-B, M-tropic viral isolate, as
previously described [54]. Briefly, freshly elutriatedmonocytes were re-suspended in Dulbecco’s Modified Ea-
gles Media (DMEM) containing 2 mM L-glutamine (Invi-
trogen), 10% heat-inactivated human serum, 100 μg/ml
gentamicin, and 10 μg/ml ciprofloxacin (Sigma); HIV-
1ADA was then added at MOI 0.01, and monocytes cul-
tured overnight (for 12 hours). After the 12 hours culture,
monocytes were washed 3 times with PBS to remove free
viral particles, and used for co-culture experiments. MDM
were obtained from monocytes by culture for 7 days in
DMEM containing 2 mM L-glutamine (Invitrogen), 10%
heat-inactivated human serum, 100 μg/ml gentamicin,
and 10 μg/ml ciprofloxacin (Sigma) in the presence of
1,000 U/ml MCSF as previously described [54]. For ex-
periments testing the effects of CCR5 blockers, mono-
cytes and MDM were treated with 5 μM TAK-779 or
5 μM maraviroc for 30 min prior to viral exposure.
Both TAK-779 and maraviroc were obtained from the
NIH AIDS Research and Reference Reagent Program.
All reagents were prescreened for endotoxin (<10 pg/
ml, Associates of Cape Cod, Woods Hole, MA) and
mycoplasma contamination (Gen-probe II, Gen-probe,
San Diego, CA). Levels of productive viral replication were
measured in culture fluids by reverse transcriptase assay
[55], and toxicity of TAK-779 and maraviroc assessed by
alamarBlue™ assay as previously described [56].
Brain endothelial cell culture
Primary HBMEC were isolated from brain tissue obtained
during surgical removal of epileptogenic cerebral cortex in
adult patients as described previously [54,57]. Routine
evaluation by immunostaining for von-Willebrand factor,
Ulex europaeus lectin and CD31 demonstrated that cells
were > 99% pure. Freshly isolated cells were cultured on
collagen-coated 100-mm culture plates [54], and cells at
passage 2 to 4 were used in this study.
Measure of trans-endothelial electrical resistance (TEER)
For TEER measurements, HBMEC were seeded on gold-
film electrode surface (Applied BioPhysics Inc., Troy,
NY) and cultured to confluence. Confluent HBMEC
were exposed to 5 to 20 μM of TAK-799 or maraviroc;
TEER live-recorded readings were made before and after
exposures. Controls consisted of non-treated HBMEC
and cells treated with 0.1% saponin. To determine
whether any effect of CCR5 blockers on the BBB was re-
versible, HBMEC were washed after 48 hours to remove
TAK-779 or maraviroc, and TEER live-recorded readings
were made for an additional 20 to 24 hours.
Co-culture of monocytes with HBMEC
HIV-1-infected monocytes were added to confluent mono-
layers of HBMEC in 100-mm culture plates (5 monocytes
for each HBMEC), and co-cultured for 2 hours. Controls
consisted of mock-infected monocytes co-cultured with
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not cultured with HBMEC. For experiments testing the ef-
fects of CCR5 blockers, monocytes were treated with 5 μM
TAK-779 or maraviroc for 30 min before culture. Follow-
ing the 2 hours co-culture, monocytes were harvested by
washing HBMEC monolayer 3 times with PBS. Adherent
HBMEC were checked by microscopy to ensure adequate-
maximal removal of monocytes, before harvesting endo-
thelial cells by scrapping. Each cell type was pelleted by
centrifugation at 3,000-g for 10 min, followed by protein
extraction.
Protein extraction and cytoskeleton antibody microarray
Cells were lysed and protein extracted using the Protein
Extraction Kit (Full Moon Biosystems, Sunnyvale, CA) ac-
cording to the manufacturer’s protocol and protein con-
centration measured using the bicinchoninic acid assay
(Pierce, Rockford, IL). The Cytoskeleton-II protein arrays
and all reagents used for protein microarray analysis were
from Full Moon Biosystems, except Cy3-conjugated strep-
tavidin, which was from GE Healthcare Life Sciences
(Piscataway, NJ). Each Cytoskeleton-II protein array con-
tained 141 well-characterized phosphorylated antibodies
of the cytoskeletal pathway, and corresponding total anti-
bodies. To ensure reliability and consistency of results,
each array included 6 replicates of each antibody and
phospho-antibody. Additional controls on each array in-
cluded 6 positive controls consisting of Cy-3 labeled anti-
bodies, 6 negative controls containing bovine serum
albumin (BSA), and empty spots containing no antibody,
with the 6 replicates scattered throughout the array. The
antibody microarray was performed according to the
manufacturer’s protocol and slides were scanned using
Full Moon Biosystems Scanning Array Service.
Array data analysis
Each spot throughout the array was scanned to provide its
signal intensity values, including positive (spots containing
Cy-3 labeled antibodies) and negative (empty spots and
spots containing BSA) controls. For background correc-
tion, the median value of the negative control signal was
subtracted from the values of each antibody and phospho-
antibody. The background corrected signal was log2 trans-
formed and normalized by the mean value of beta-actin
signal. For each phosphorylated antibody, the background
corrected signal was normalized by the mean value of the
corresponding total antibody. The fold changes between
treatment groups were derived from ratios of geometric
mean signal intensities. Treatment groups included: con-
trol non-infected monocytes co-cultured with HBMEC
(control), HIV-infected monocytes co-cultured with
HBMEC (HIV), and HIV-infected monocytes treated with
CCR5 blockers and co-cultured with HBMEC (HIV +
TAK). ANOVA with heterogeneous variance was used forstatistical analyses of protein expression between groups,
and the Tukey-Kramer method used for multiple compar-
isons. The Benjamini-Hochberg (BH) method was then
used to control the false discovery rate. Proteins with BH
adjusted p-value less than 0.05 were considered to be dif-
ferentially expressed.
Ingenuity pathway analysis
Differentially expressed and phosphorylated proteins identi-
fied in HIV-1-infected monocytes co-cultured with HBMEC,
compared to non-infected monocytes co-cultured with
HBMEC, or infected monocytes treated with CCR5 blockers
and co-cultured with HBMEC, were analyzed using the In-
genuity Pathways Analysis 3.0 (IPA) (Ingenuity Systems).
The networks obtained through IPA software describe func-
tional relationships between proteins products based on
known interactions, biological functions and canonical path-
ways. Using a false discovery rate of 0.05, only phospho-
proteins upregulated or downregulated by at least 1.5-fold
were considered; and for non-phosphorylated proteins, only
those upregulated or downregulated by at least 2-fold were
considered.
Monocyte adhesion to an in vitro BBB model
For adhesion assays, HBMEC were plated on 96-well
collagen-coated black-bottom plates and cultured to con-
fluence. Infected monocytes (2.5 × 105 cells) treated or
non-treated with CCR5 blockers or CCR5 antibodies were
labeled with 5-carboxyfluorescein diacetate, acetoxymethyl
ester (CFDA), 10-μM/1 × 106 for 1 hour, and co-cultured
with HBMEC for 15 min. HBMEC were then washed 3
times with PBS, and the number of adherent monocytes
was quantified by spectrophotometry (absorbance 492-
nm, emission 517-nm), with a standard curve derived
from a serial dilution of a known number of CFDA-
labeled monocytes.
RNA isolation and quantitative real-time PCR (qRT-PCR)
Brain tissues (cortex) from HIV-1-seropositive patients
with or without neurocognitive impairment, and HIV-
seronegative controls were obtained from the National Neu-
roAIDS Tissue Consortium and our Department of
Pharmacology and Experimental Neuroscience brain bank.
The clinical histories of all brain tissue donors are detailed
in Table 3. Total RNA was extracted from brain tissues
using the Trizol reagent (Life Technologies-Ambion,
Austin, TX) according to the manufacturer’s protocol
and further cleaned using Total RNA cleanup kit
(Qiagen, Valencia, CA). RNA yield and quality were checked
using a NanoDrop spectrophotometer (NanoDrop
Technologies, Wilmington, DE) and for all samples ab-
sorbance ratio of 260/280 was ≥ 2. For each sample,
cDNA was generated from 2 μg RNA using the High
Capacity cDNA Reverse Transcription Kit (Applied
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tion system was used and quantification performed
using the standard curve method as described in the
Applied Biosystems StepOnePlus™ protocol. All reagents
and primers were obtained from Applied Biosystems and
for endogenous controls, each gene expression was nor-
malized to GAPDH. Primer IDs were Rac1:
Hs01902432_s1, cortactin: Hs01124225_m1, and GAPDH
Hs99999905_m1.
Western blot analyses
Protein extraction and Western blot analyses were per-
formed as previously described [30,56]. ERK1/2 antibodies
were from Cell Signaling (Danvers, MA), while all other
antibodies were from Full Moon Biosystems. Following
Western blot with phosphorylated antibodies, membranes
were stripped using Restore Western Blot Stripping Buffer
(Pierce) and re-blotted with the corresponding total anti-
body, then stripped again and re-blotted with β-actin anti-
body to confirm equal loading. Results were expressed as
ratios of relative intensity of the phospho-protein to total
protein, or β-actin.
Immunofluorescence and confocal microscopy
Five-micrometer sections were cut from each human brain
tissue, mounted on glass slides, fixed, permeabilized, and
incubated 1 hour in PBS containing 3% BSA to block for
non-specific binding. Tissues were incubated overnight with
antibodies to phospho-Rac1(S71) and CD163, ionized calcium
binding adapter molecule-1 (IBA1), glial fibrillary acidic pro-
tein (GFAP), microtubule-associated protein-2 (MAP2), or
glucose transporter-1 (GLUT1) (Abcam, Cambridge, MA),
followed by staining (1 hour in the dark at room temperature)
with secondary antibodies coupled with Alexa Fluor-488 or
−635 (Invitrogen) at 1:500 dilutions. Stained tissues were
washed in PBS and mounted in Prolong Gold anti-fade re-
agent containing DAPI (Molecular Probes, Grand Island, NY)
and examined under an Olympus FV500-IX 81 confocal laser
scanning imaging system. The triple laser lines excitation were
405-nm for nucleus-stains; 484-nm for CD163, GFAP, MAP2,
IBA1, or GLUT1, and 635-nm for pRac1(S71). A 4th laser line
(excitation: 543-nm. Emission: 595-nm) was used to detect
auto-fluorescent pigments.
Detection of HIV-1 in infected monocytes
Freshly elutriated monocytes were re-suspended in DMEM
with or without MCSF as described above, exposed to HIV-
1 (MOI: 0.01) and cultured for 2 hours, 4 hours, 12 hours,
24 hours, and 48 hours. Cells were then washed three times
with PBS to remove excess viral particles, and cellular RNA
extracted using the Trizol reagent. Extracted RNA were fur-
ther cleaned using the Qiagen RNA Cleanup kit (Qiagen,
Valencia, CA). HIV-1 gag mRNA was quantified by real-
time PCR as described above, using custom ordered probesand gag primers from Applied Biosystems [probe sequence:
FAM-CAT CAA TGA GGA AGC TGC AGA ATG GGA
TAGA-MGB; Forward (FW) primer: 5′-ACA TCA AGC
CAT GCA AAT-3′ (nucleotide 1368–1388); Reverse (RV)
primer: 5′-ATC TGG CCT GGT GCA ATA GG-3′ (nu-
cleotide 1472–1453)]. All reactions were normalized to sam-
ple GAPDH (primers ID# Hs99999905_m1, Applied
Biosystems).
Reverse-transcription PCR (RT-PCR) was performed
using 20 ng RNA, Promega PCR master mix, and the fol-
lowing Tat primers: FW primer: 5′-GGA ATT CAC CAT
GGA GCC AGT AGA TCC T-3′; RV primer: 5′-CGG
GAT CCC TAT TCC TTC GGG CCT GT-3′ custom or-
dered from Integrated DNA Technology Inc. (Coralville,
Iowa), in a 25 μl total reaction volume. Tat PCR reaction
cycle was as followed: 94°C, 10 min initial denaturation;
followed by 70 cycles of 94°C for 1 min, 60°C for 35 sec-
onds, and final elongation at 72°C for 10 min. RT-PCR re-
actions were run on a 1.5% agarose gel and images
captured using Syngene G-box (Syngene, Frederick, MD).
For immunofluorescence imaging of infected monocytes,
50,000 freshly elutriated monocytes were placed on poly-l-
lysine coated glass coverslips, cultured for 2 to 48 hours in
DMEM without MCSF in the presence of HIV-1ADA (MOI:
0.01) as described above. Cells were then fixed for 20 min in
cold methanol/acetone (1:1), permeabilized, and blocked for
non-specific binding by incubation with 3% bovine serum
albumin in PBS (10 min at 4°C). Cells were incubated with
5 μg/ml gp120 monoclonal antibody (antibody 697-30D,
NIH AIDS Reagent Program) overnight at 4°C, washed 3
times with PBS, 3 to 5 minutes each wash, followed by
staining (1 hour in the dark at room temperature) with sec-
ondary antibodies coupled with Alexa-488 (1:500 dilution).
Stained cells were then washed with PBS 3 times, 3 to 5 mi-
nutes each wash, and mounted in Prolong Gold anti-fade
reagent containing DAPI.
Ethical approval
Removal of epileptogenic cerebral cortex tissue from adult
patients, and its use for HBMEC isolation, were done after
obtaining patient’s consent and ethical approval by the
University of Arizona institutional review board (IRB), and
primary HBMEC provided by Drs. Marlys Witte and
Michael Bernas (University of Arizona, Tucson, AZ)
[57]. Monocytes were obtained from adult human
donor leukocytes after obtaining donor’s consent and
the University of Nebraska Medical Center IRB ap-
proval. Post-mortem brain tissues obtained from brain
banks did not have personal donor identifier, and did
not require ethical approval for use in research.
Statistical analyses
Data were analyzed by t-test (two-tailed) for two-group
comparisons and one- or two-way ANOVA followed by
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5.0b. (GraphPad Software, La Jolla, CA). Threshold of sig-
nificance level was 0.05.
Additional files
Additional file 1: Figure S1. Molecular networks of differentially
expressed and phosphorylated proteins in monocytes following monocyte-
endothelial communications. Interacting pathways constructed using IPA
show upregulation of cytoskeletal proteins in HIV-infected monocytes
following co-culture with HBMEC (A), and downregulation of these proteins
in HIV-infected monocytes treated with TAK-779 and co-culture with HBMEC
(B). The most significant molecular networks for differentially expressed
proteins were associated with Cell-To-Cell Signaling and Interaction, Cell
Death and Survival, and Developmental Disorders (A, B). Analysis of differentially
phosphorylated proteins show increased phosphorylation of some proteins in
HIV-infected monocytes following co-culture with HBMEC (C), and decreased
phosphorylation when infected monocytes were treated with TAK-779 before
co-culture with HBMEC (D). The most significant molecular networks for these
differentially phosphorylated proteins were associated with Cellular Movement,
Cell Cycle, Cellular Assembly and Organization (C, D). These top molecular
networks identified had 11 to 15 focus proteins (proteins significantly up- or
down-regulated). The intensity of node colors indicates the degree of up- (red)
or down- (green) regulation. White color nodes are non-focus proteins: proteins
that are biologically relevant to the pathways but were not identified as
differentially expressed in our protein microarray analysis. Solid lines represent
known direct interactions, dotted lines represent suspected or indirect
interactions. Abbreviations (focus proteins are italicized): MAP2K: Mitogen-
Activated Protein Kinase Kinase; NFAT: Nuclear Factor of Activated T-cells; IG:
Immunoglobulin; AP1: Activator Protein-1; PLC: Phospholipase-C; CAMK: Ca2
+/calmodulin-Dependent Protein Kinase; BCAR1(p130Cas): Breast Cancer
Anti-Estrogen Resistance-1; ERK1/2: Extracellular-signal-regulated Kinase1/2;
HSP90: Heat Shock Protein-90; PRKCA: Protein Kinase-C alpha; RAF1: V-Raf-1
Murine Leukemia Viral Oncogene Homolog-1; EZR: Ezrin; PP2A: Protein
Phosphatase-2; ROCK: Rho Kinase; MLC: Myosin Light Chain; RAC1: Ras-
related C3 botulinum toxin substrate-1; PDGF: Platelet-Derived Growth
Factor; BCR: B-Cell Receptor; CTTN: Cortactin; NF2(Merlin): neurofibromin-2;
PAK: p21 Activated Kinase; PTK2(FAK): Protein Tyrosine Kinase-2; VASP:
Vasodilator-Stimulated Phosphoprotein; WASF1: WAS Protein Family,
Member-1; PLCB3: Phospholipase C, Beta-3.
Additional file 2: Table S1. Molecular and cellular functions associated
with differentially expressed and phosphorylated proteins in HIV-infected
monocytes following monocyte-endothelial interactions.
Additional file 3: Table S2. Canonical Pathways associated with
differentially expressed and phosphorylated proteins in HIV-infected
monocytes following monocyte-endothelial interactions.
Additional file 4: Figure S2. Detection of HIV-1 gag and tat mRNA in
infected monocytes. Freshly elutriated monocytes were exposed to HIV-
1ADA (MOI: 0.01) and culture for 2 to 48 hours in media with or without
MCSF as detailed in the Method section. Control consisted of non-
infected monocytes (0 hour). Quantitative real-time PCR for HIV-1 gag
mRNA (A, B) showed that gag mRNA was present in monocytes from
2 hour post elutriation / infection, with more gag copies numbers in
monocytes cultured in media without MCSF (B), compared to monocytes
cultured in media containing MCSF (A). Gag mRNA copy numbers
decreased over time but was still detectable in infected cells. Reverse-
transcription PCR targeting tat mRNA (C, D) also showed detectable tat
mRNA in both monocytes cultured in media with (C) and without (D)
MCSF from 2 hours post elutriation / infection.
Additional file 5: Figure S3. Detection of HIV-1 gp120 in infected
monocytes. Freshly elutriated monocytes were exposed to HIV-1ADA and
culture for 2 to 48 hours in media without MCSF as detailed in the
Method section. Control consisted of non-infected monocytes (0 h).
Immunofluorescence microscopy showed positive staining for HIV-1
gp120 from 2 hours post elutriation / infection.
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